Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-179082
Filing Date
2025-08-12
Accepted
2025-08-12 17:12:49
Documents
18
Effectiveness Date
2025-08-12

Document Format Files

Seq Description Document Type Size
1 S-8 d24105ds8.htm S-8 43580
2 EX-5.1 d24105dex51.htm EX-5.1 7379
3 EX-23.1 d24105dex231.htm EX-23.1 1674
4 EX-FILING FEES d24105dexfilingfees.htm   iXBRL EX-FILING FEES 12907
5 GRAPHIC g24105dsp1.jpg GRAPHIC 3060
6 GRAPHIC g24105g0811220021442.jpg GRAPHIC 1649
7 GRAPHIC g24105g0811220021649.jpg GRAPHIC 1898
8 GRAPHIC g24105g0811220022670.jpg GRAPHIC 5595
  Complete submission text file 0001193125-25-179082.txt   203813

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT d24105dexfilingfees_htm.xml XML 5276
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-289544 | Film No.: 251207836
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)